RecruitingNCT04535843
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
Sponsor
Huashan Hospital
Enrollment
500 participants
Start Date
Feb 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The present study is a prospective cohort study aiming to improve the clinical capacity in the diagnosis and natural history of Chinese patients with myasthenia gravis (MG). 300 MG patients are planned to recruit, document and prospectively follow up. Management of screening test and cohort manifestation are studied.
Eligibility
Min Age: 0 YearsMax Age: 90 Years
Inclusion Criteria5
- fluctuating muscle weakness and fatigability, along with one of the below:
- more than 10% amplitude decrement in low frequency repetitive nerve stimulation,less than 10% amplitude increment in high frequency repetitive nerve stimulation;
- anti-AChR or MuSK antibody positivity;
- positive to the neostigmine test;
- understanding and assigning the informed consent form, and having a good compliance with the follow up.
Exclusion Criteria2
- excluding the possible diagnosis of Lambert-Eaton syndrome, congenital myasthenia syndrome,botulism injection, chronic progressive extraocular ophthalmoplegia, etc;
- poor compliance to the follow up.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERBiomarkers and omics data
To detect disease-related biomarkers and omics data, in this prospective MG cohort.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04535843
Related Trials
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT0729417010 locations
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT072844209 locations
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT073041543 locations
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT0641495440 locations
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT072175878 locations